Most Read Articles
Roshini Claire Anthony, 11 Dec 2020

Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.

Stephen Padilla, 22 Jun 2020
A dietary pattern (DP) characterized by high intakes of eggs, fish, milk, and other dairy products appears to confer protective benefits against incident cardiovascular disease (CVD) in women, reveals a study.

BNP predicts adverse events in apical hypertrophic cardiomyopathy

26 Aug 2020
There are many heart diseases that are relatively unheard of despite the stark prevalence of heart diseases in our region.

Elevated levels of B-type natriuretic peptide (BNP) may help predict the incidence of adverse events and related outcomes in patients with apical hypertrophic cardiomyopathy (HCM), a recent study has found.

The study included 144 patients with apical HCM, in whom the median BNP concentration was 188.5 pg/mL. Over 9.5 years of follow-up, 23.6 percent (n=34) of the cohort developed HCM-related adverse outcomes, such as sudden death, stroke-related death, non-fatal stroke, and heart failure hospitalization, among others.

The researchers saw that BNP levels at enrolment were significantly higher in patients who did vs did not develop the combined HCM endpoints (334.4 vs 133.4 pg/mL; p<0.001).

Receiver operating characteristic (ROC) curve analysis showed that at an optimal cutoff of ≥226.0 pg/mL, BNP was sufficiently indicative of the study endpoint, with an area under the ROC curve of 0.756, and sensitivity and specificity values of 73.5 percent and 68.2 percent, respectively.

Twenty-five patients with high BNP developed the combined endpoint over a median of 8.9 years, yielding a rate of 41.7 percent. Of these, there was one case of sudden death, four stroke-related deaths, seven non-fatal strokes, and 10 heart failure hospitalizations. In contrast, only nine episodes (10.7 percent) were reported in the low-BNP participants, over a longer follow-up period of 9.8 years.

Multivariable analysis confirmed that the risk for combined HCM-related adverse events was significantly elevated in patients with BNP >226.0 pg/mL (adjusted hazard ratio, 4.46, 95 percent confidence interval, 2.07–9.61; p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Dec 2020

Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.

Stephen Padilla, 22 Jun 2020
A dietary pattern (DP) characterized by high intakes of eggs, fish, milk, and other dairy products appears to confer protective benefits against incident cardiovascular disease (CVD) in women, reveals a study.